SCHEMBL5550219

SCHEMBL5550219

O=c1c(Cl)nc2ccccc2n1CCc1ccccn1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.47
▸ PYGM P11217 1/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ GABRA1 P14867 1/20 0.46
▸ GABRA5 P31644 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ ALOX15 P16050 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ MKNK1 Q9BUB5 1/20 0.44
▸ MKNK2 Q9HBH9 1/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.43
▸ CFTR P13569 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ RECQL P46063 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547053 0.79 KDM4E (0.49) HSD17B10KDM4EALDH1A1CYP1A2CYP2C9
SCHEMBL12598788 0.77 CXCR4 (0.64) KDM4EALDH1A1CYP1A2ALOX15TSHR
SCHEMBL2084334 0.77 VDR (0.50) HSD17B10KDM4EALDH1A1CYP1A2CYP2C19
SCHEMBL6870748 0.77 KDM4E (0.47) HSD17B10PYGMKDM4EALDH1A1ALOX15
SCHEMBL5545639 0.75 KDM4E (0.67) HSD17B10KDM4EALDH1A1CYP1A2SMN1; SMN2
SCHEMBL5549623 0.75 TOP2A (0.60) HSD17B10PYGMKDM4EALDH1A1CYP1A2
SCHEMBL29205391 0.74 HRH1 (0.54) KDM4EALDH1A1SMN1; SMN2ALOX15TSHR
SCHEMBL30281772 0.74 HRH1 (0.54) KDM4EALDH1A1SMN1; SMN2ALOX15TSHR
SCHEMBL5547083 0.73 KMT2A (0.56) HSD17B10KDM4EALDH1A1CYP2C19SMN1; SMN2
SCHEMBL4985348 0.73 HRH1 (0.52) HSD17B10KDM4EGABRA1GABRA5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1711184-B1 (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY JANSSEN PHARMACEUTICA NV (BE) 2007-07-18 — — EP disclosed
EP-1711184-B1 (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY JANSSEN PHARMACEUTICA NV (BE) 2007-07-18 — — EP disclosed
EP-1711184-A1 (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY JANSSEN PHARMACEUTICA N.V. (BE) 2006-10-18 — — EP disclosed
WO-2005067932-A1 (3-OXO-3, 4-DIHYDRO-QUINOXALIN-2-YL-AMINO) -BENZAMIDE DERIVATIVES AND RELATED COMPOUND AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY JANSSEN PHARMACEUTICA, N.V. (BE) 2005-07-28 — — WO disclosed
US-20050148586-A1 Quinoxalinones JANSSEN PHARMACEUTICA, N.V. (BE) 2005-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148586-A1 Quinoxalinones SLC5A2, GPR119, GLS2 HSD17B10 366/4885PYGM 271/4885KDM4E 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback